Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 250-654-8 | CAS number: 31482-56-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 23 May 2017 to 7 June 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
- Reference substance name:
- 3-[ethyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile
- EC Number:
- 250-654-8
- EC Name:
- 3-[ethyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile
- Cas Number:
- 31482-56-1
- Molecular formula:
- C17H17N5O2
- IUPAC Name:
- 3-[ethyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8 weeks old
- Weight at study initiation: 182-199 g
- Fasting period before study: overnight before treatment and three hours following treatment
- Housing: 3 animals/Type II polypropylene/polycarbonate cages
- Diet: ad libitum
- Water: tap water ad libitum
- Acclimation period: 5-6 days
ENVIRONMENTAL CONDITIONS
- Temperature: 20.-25.0°C
- Humidity: 31-62%
- Air changes: 15-20 per hr
- Photoperiod: 12 hrs dark / 12 hrs light
IN-LIFE DATES: 23 May 2017 to 7 June 2017
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 200 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg bw
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: selected by the Study Director to be that which is most likely to produce mortlaity in some dosed animals. - Doses:
- 2000 mg/kg/bw
- No. of animals per sex per dose:
- Two groups of three females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations were performed on all animals at 30 min, 1, 2, 3, 4 and 6 hours after dosing and daily thereafter. Body weight was recorded on the day before treatment (day -1), the day of treatment (day 0) and weekly thereafter.
- Necropsy of survivors performed: yes. After examination of the external appearance, the cranial, thoracic and the abdominal cavities were opened and the organs and the tissues were observed. Macroscopic abnormalities were recorded.
- Other examinations performed: clinical signs, body weight, organ weights, histopathology, other:
Clincal observations were performed on the skin, fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- One animal in the confirmatory group
- Clinical signs:
- other: Reddish coloured faeces were observed 6 hours after treatment and on the day after treatment. Reddish coloured urine was observed on the day after treatment. Besides this, there were no systemic clinical signs noted in any animal throughout the study.
- Gross pathology:
- There was no evidence of the macroscopic observations at necropsy in the surviving animals.
The following observations were recorded in the animal found dead: dark red diffuse discolouration of all lobes of the non-collapsed lungs, reddish foamy material in the trachea, red liquid material mixed with the diet in the digestive content of the stomach, duodenum, jejunum, ileum and cecum.
Applicant's summary and conclusion
- Interpretation of results:
- other: Not classified according to EU criteria
- Conclusions:
- Under the conditions of the study, the acute LD50 value of the test material was found to be > 2000 mg/kg bw in female Crl:WI rats.
- Executive summary:
The single-dose oral toxicity of the test material was performed according to the acute toxic class method in line with standardised guidelines OECD 423 and EU Method B.1 tris and under GLP conditions.
During the study two groups of three female Crl:WI rats were treated with the test material at a dose of 2000 mg/kg bw (Group 1 and 2). A single oral treatment was carried out by gavage for each animal after an overnight food withdrawal. Food was made available again 3 hours after treatment. The test material was administered formulation in PEG 400 at a concentration of 200 mg/mL at a dose volume of 10 mL/kg bw. Initially, three females (Group 1) were treated at 2000 mg/kg bw. As no mortality was observed, a confirmatory group (Group 2) was treated at the same dose level. Only one death was observed in the confirmatory group; therefore no further testing was required in line with the guidelines. Clinical observations were performed at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter. Body weight was measured on days -1, 0, 7 and 14 (before necropsy). All animals were subjected to a necropsy and a macroscopic examination.
The test material caused one mortality in one animal out of six. Reddish coloured faeces were observed 6 hours after treatment and on the day after treatment. Reddish coloured urine was observed on the day after treatment. There were no additional clinical symptoms observed in any animal during the study. There were no treatment-related body weight changes. However, slight body loss was observed in one animal during the first week of observation. Body weight gains of treated animals during the study showed no indication of a test material-related effect. There was no evidence of the macroscopic observations at necropsy in any of the surviving animals. The following observations were recorded in the animals found dead: dark red diffuse discolouration of all lobes of non-collapsed lungs, reddish foamy material in the trachea, red liquid material mixed with the diet in the digestive contents of the stomach, duodenum, jejunum, ileum and cecum.
Under the conditions of the study, the acute LD50 value of the test material was found to be > 2000 mg/kg bw in female Crl:WI rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.